Logo image of PLX

PROTALIX BIOTHERAPEUTICS INC (PLX) Stock Fundamental Analysis

USA - NYSEARCA:PLX - US74365A3095 - Common Stock

2.105 USD
+0.06 (+3.19%)
Last: 9/23/2025, 11:11:20 AM
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PLX. PLX was compared to 538 industry peers in the Biotechnology industry. PLX has an average financial health and profitability rating. PLX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

PLX had positive earnings in the past year.
PLX had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: PLX reported negative net income in multiple years.
In the past 5 years PLX reported 4 times negative operating cash flow.
PLX Yearly Net Income VS EBIT VS OCF VS FCFPLX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of 8.00%, PLX belongs to the top of the industry, outperforming 92.57% of the companies in the same industry.
Looking at the Return On Equity, with a value of 12.57%, PLX belongs to the top of the industry, outperforming 93.49% of the companies in the same industry.
The Return On Invested Capital of PLX (12.68%) is better than 94.80% of its industry peers.
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROIC 12.68%
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PLX Yearly ROA, ROE, ROICPLX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

Looking at the Profit Margin, with a value of 10.13%, PLX belongs to the top of the industry, outperforming 92.19% of the companies in the same industry.
PLX's Operating Margin of 13.28% is amongst the best of the industry. PLX outperforms 93.31% of its industry peers.
PLX has a better Gross Margin (57.53%) than 77.51% of its industry peers.
In the last couple of years the Gross Margin of PLX has declined.
Industry RankSector Rank
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
PLX Yearly Profit, Operating, Gross MarginsPLX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PLX is creating some value.
PLX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PLX has more shares outstanding
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PLX Yearly Shares OutstandingPLX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLX Yearly Total Debt VS Total AssetsPLX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -1.63, we must say that PLX is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.63, PLX is in line with its industry, outperforming 54.46% of the companies in the same industry.
There is no outstanding debt for PLX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.63
ROIC/WACC1.23
WACC10.29%
PLX Yearly LT Debt VS Equity VS FCFPLX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 2.72 indicates that PLX has no problem at all paying its short term obligations.
With a Current ratio value of 2.72, PLX is not doing good in the industry: 67.29% of the companies in the same industry are doing better.
PLX has a Quick Ratio of 1.84. This is a normal value and indicates that PLX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.84, PLX is doing worse than 76.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 1.84
PLX Yearly Current Assets VS Current LiabilitesPLX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

PLX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 135.00%, which is quite impressive.
Looking at the last year, PLX shows a very strong growth in Revenue. The Revenue has grown by 62.79%.
The Revenue has been decreasing by -0.48% on average over the past years.
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%

3.2 Future

PLX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 238.30% yearly.
PLX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.15% yearly.
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PLX Yearly Revenue VS EstimatesPLX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
PLX Yearly EPS VS EstimatesPLX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 6

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 30.07, the valuation of PLX can be described as expensive.
93.31% of the companies in the same industry are more expensive than PLX, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 27.41. PLX is around the same levels.
The Price/Forward Earnings ratio is 3.82, which indicates a rather cheap valuation of PLX.
Based on the Price/Forward Earnings ratio, PLX is valued cheaper than 99.07% of the companies in the same industry.
PLX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.87.
Industry RankSector Rank
PE 30.07
Fwd PE 3.82
PLX Price Earnings VS Forward Price EarningsPLX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, PLX is valued cheaply inside the industry as 94.61% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.08
PLX Per share dataPLX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6

4.3 Compensation for Growth

PLX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PLX's earnings are expected to grow with 238.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y328.35%
EPS Next 3Y238.3%

More info and screens

0

5. Dividend

5.1 Amount

PLX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTALIX BIOTHERAPEUTICS INC

NYSEARCA:PLX (9/23/2025, 11:11:20 AM)

2.105

+0.06 (+3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-12 2025-11-12
Inst Owners11.2%
Inst Owner Change46.32%
Ins Owners4.18%
Ins Owner Change0%
Market Cap167.83M
Analysts80
Price Target14.28 (578.38%)
Short Float %5.04%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-182.51%
Min EPS beat(2)-265.02%
Max EPS beat(2)-100%
EPS beat(4)1
Avg EPS beat(4)-90.87%
Min EPS beat(4)-265.02%
Max EPS beat(4)27.3%
EPS beat(8)2
Avg EPS beat(8)-112.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.6%
Min Revenue beat(2)-53.64%
Max Revenue beat(2)14.45%
Revenue beat(4)2
Avg Revenue beat(4)-8.41%
Min Revenue beat(4)-53.64%
Max Revenue beat(4)14.45%
Revenue beat(8)5
Avg Revenue beat(8)3.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-21.43%
EPS NQ rev (3m)10%
EPS NY rev (1m)0%
EPS NY rev (3m)-58.06%
Revenue NQ rev (1m)0.43%
Revenue NQ rev (3m)-25.25%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-30.59%
Valuation
Industry RankSector Rank
PE 30.07
Fwd PE 3.82
P/S 2.71
P/FCF N/A
P/OCF N/A
P/B 3.36
P/tB 3.36
EV/EBITDA 15.08
EPS(TTM)0.07
EY3.33%
EPS(NY)0.55
Fwd EY26.15%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.78
BVpS0.63
TBVpS0.63
PEG (NY)0.09
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 8%
ROE 12.57%
ROCE 15.12%
ROIC 12.68%
ROICexc 18.89%
ROICexgc 18.89%
OM 13.28%
PM (TTM) 10.13%
GM 57.53%
FCFM N/A
ROA(3y)-4.31%
ROA(5y)-11.99%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.72%
GM growth 5Y-7.42%
F-Score6
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 91.23%
Cap/Sales 2.02%
Interest Coverage 10.74
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 1.84
Altman-Z -1.63
F-Score6
WACC10.29%
ROIC/WACC1.23
Cap/Depr(3y)84.19%
Cap/Depr(5y)86.74%
Cap/Sales(3y)1.83%
Cap/Sales(5y)2.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y337.67%
EPS Next 2Y328.35%
EPS Next 3Y238.3%
EPS Next 5YN/A
Revenue 1Y (TTM)62.79%
Revenue growth 3Y11.67%
Revenue growth 5Y-0.48%
Sales Q2Q%16.21%
Revenue Next Year12.26%
Revenue Next 2Y40.47%
Revenue Next 3Y44.15%
Revenue Next 5YN/A
EBIT growth 1Y155.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.67%
OCF growth 3YN/A
OCF growth 5YN/A